https://médecine.top/index.php?action=history&feed=atom&title=Leuc%C3%A9mies
Leucémies - Historique des versions
2026-09-04T00:27:42Z
Historique des révisions pour cette page sur le wiki
MediaWiki 1.35.2
https://médecine.top/index.php?title=Leuc%C3%A9mies&diff=5409&oldid=prev
Julien : /* Lignée myéloïde */
2025-07-02T13:21:19Z
<p><span dir="auto"><span class="autocomment">Lignée myéloïde</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 2 juillet 2025 à 13:21</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l39" >Ligne 39 :</td>
<td colspan="2" class="diff-lineno">Ligne 39 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Lignée myéloïde ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Lignée myéloïde ==</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">=== Leucémie myéloïde aiguë (LMA) ===</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Fichier:Hierarchical classification of the International Consensus Classification of AML 2022.png|800px|vignette|centré|Source: https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022]]</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Fichier:Hierarchical classification of the International Consensus Classification of AML 2022.png|800px|vignette|centré|Source: https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022]]</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">=== Leucémie myéloïde aiguë (LMA) ===</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Caractéristiques:</u> Association avec coagulopathie, [[coagulation intravasculaire disséminée (CIVD)]]. 7 types</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Caractéristiques:</u> Association avec coagulopathie, [[coagulation intravasculaire disséminée (CIVD)]]. 7 types</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** Bilan: cytométrie de flux, panel myéloïde</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** Bilan: cytométrie de flux, panel myéloïde</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Leuc%C3%A9mies&diff=5408&oldid=prev
Julien : /* Lignée myéloïde */
2025-07-02T13:20:39Z
<p><span dir="auto"><span class="autocomment">Lignée myéloïde</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 2 juillet 2025 à 13:20</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l39" >Ligne 39 :</td>
<td colspan="2" class="diff-lineno">Ligne 39 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Lignée myéloïde ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Lignée myéloïde ==</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>[[Fichier:Hierarchical classification of the International Consensus Classification of AML 2022.png|800px|vignette|centré|Source: <del class="diffchange diffchange-inline">[test </del>https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022<del class="diffchange diffchange-inline">]</del>]]</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>[[Fichier:Hierarchical classification of the International Consensus Classification of AML 2022.png|800px|vignette|centré|Source: https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022]]</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Leucémie myéloïde aiguë (LMA) ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Leucémie myéloïde aiguë (LMA) ===</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Caractéristiques:</u> Association avec coagulopathie, [[coagulation intravasculaire disséminée (CIVD)]]. 7 types</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Caractéristiques:</u> Association avec coagulopathie, [[coagulation intravasculaire disséminée (CIVD)]]. 7 types</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Leuc%C3%A9mies&diff=5407&oldid=prev
Julien : /* Lignée myéloïde */
2025-07-02T13:20:18Z
<p><span dir="auto"><span class="autocomment">Lignée myéloïde</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 2 juillet 2025 à 13:20</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l39" >Ligne 39 :</td>
<td colspan="2" class="diff-lineno">Ligne 39 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Lignée myéloïde ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Lignée myéloïde ==</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>[[Fichier:Hierarchical classification of the International Consensus Classification of AML 2022.png|<del class="diffchange diffchange-inline">500px</del>|vignette|centré|Source: [https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022]]]</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>[[Fichier:Hierarchical classification of the International Consensus Classification of AML 2022.png|<ins class="diffchange diffchange-inline">800px</ins>|vignette|centré|Source: [<ins class="diffchange diffchange-inline">test </ins>https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022]]]</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Leucémie myéloïde aiguë (LMA) ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Leucémie myéloïde aiguë (LMA) ===</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Caractéristiques:</u> Association avec coagulopathie, [[coagulation intravasculaire disséminée (CIVD)]]. 7 types</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Caractéristiques:</u> Association avec coagulopathie, [[coagulation intravasculaire disséminée (CIVD)]]. 7 types</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Leuc%C3%A9mies&diff=5406&oldid=prev
Julien : /* Lignée myéloïde */
2025-07-02T13:19:57Z
<p><span dir="auto"><span class="autocomment">Lignée myéloïde</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 2 juillet 2025 à 13:19</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l39" >Ligne 39 :</td>
<td colspan="2" class="diff-lineno">Ligne 39 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Lignée myéloïde ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Lignée myéloïde ==</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">[[Fichier:Hierarchical classification of the International Consensus Classification of AML 2022.png|500px|vignette|centré|Source: [https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022]]]</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Leucémie myéloïde aiguë (LMA) ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Leucémie myéloïde aiguë (LMA) ===</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Caractéristiques:</u> Association avec coagulopathie, [[coagulation intravasculaire disséminée (CIVD)]]. 7 types</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Caractéristiques:</u> Association avec coagulopathie, [[coagulation intravasculaire disséminée (CIVD)]]. 7 types</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Leuc%C3%A9mies&diff=5127&oldid=prev
Julien : /* Leucémie myéloïde aiguë (LMA) */
2024-05-13T15:44:47Z
<p><span dir="auto"><span class="autocomment">Leucémie myéloïde aiguë (LMA)</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 13 mai 2024 à 15:44</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l45" >Ligne 45 :</td>
<td colspan="2" class="diff-lineno">Ligne 45 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Complication:</u> [[syndrome de lyse tumorale]]</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Complication:</u> [[syndrome de lyse tumorale]]</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement:</u></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement:</u></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>*# Induction: chimiothérapie pour induire la rémission complète de l'AML</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>*# <ins class="diffchange diffchange-inline">'''</ins>Induction:<ins class="diffchange diffchange-inline">''' </ins>chimiothérapie pour induire la rémission complète de l'AML</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>*# Consolidation: chimiothérapie de consolidation intensive, greffe de cellules souches hématopoïétiques (autologue ou allogénique) chez les patients jeunes avec meilleur score de performance</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>*# <ins class="diffchange diffchange-inline">'''</ins>Consolidation:<ins class="diffchange diffchange-inline">''' </ins>chimiothérapie de consolidation intensive, greffe de cellules souches hématopoïétiques (autologue ou allogénique) chez les patients jeunes avec meilleur score de performance</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==== Leucémie promyélocytaire aiguë ====</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==== Leucémie promyélocytaire aiguë ====</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Fichier:Promyélocytes atypiques avec agots d'Auer.png|centre|150px|vignette|Promyélocytes atypiques avec '''fagots d'Auer''']]</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Fichier:Promyélocytes atypiques avec agots d'Auer.png|centre|150px|vignette|Promyélocytes atypiques avec '''fagots d'Auer''']]</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Leuc%C3%A9mies&diff=5126&oldid=prev
Julien : /* Leucémie myéloïde aiguë (LMA) */
2024-05-13T15:43:19Z
<p><span dir="auto"><span class="autocomment">Leucémie myéloïde aiguë (LMA)</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 13 mai 2024 à 15:43</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l43" >Ligne 43 :</td>
<td colspan="2" class="diff-lineno">Ligne 43 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** Bilan: cytométrie de flux, panel myéloïde</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** Bilan: cytométrie de flux, panel myéloïde</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Frottis périphérique:</u> Le diagnostic d’une LMA est posé si l’on trouve '''≥20% de blastes myéloïdes dans la moelle ou le sang périphérique''' ou si une tumeur extramédullaire se compose de blastes myéloïdes.<ref>https://www.revmed.ch/RMS/2008/RMS-158/Les-leucemies-aigues</ref></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Frottis périphérique:</u> Le diagnostic d’une LMA est posé si l’on trouve '''≥20% de blastes myéloïdes dans la moelle ou le sang périphérique''' ou si une tumeur extramédullaire se compose de blastes myéloïdes.<ref>https://www.revmed.ch/RMS/2008/RMS-158/Les-leucemies-aigues</ref></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* <u>Complication:</u> syndrome de lyse tumorale</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* <u>Complication:</u> <ins class="diffchange diffchange-inline">[[</ins>syndrome de lyse tumorale<ins class="diffchange diffchange-inline">]]</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement:</u></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement:</u></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*# Induction: chimiothérapie pour induire la rémission complète de l'AML</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*# Induction: chimiothérapie pour induire la rémission complète de l'AML</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Leuc%C3%A9mies&diff=5125&oldid=prev
Julien : /* Leucémie lymphoblastique aiguë (LLA) */
2024-05-13T15:42:54Z
<p><span dir="auto"><span class="autocomment">Leucémie lymphoblastique aiguë (LLA)</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 13 mai 2024 à 15:42</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l7" >Ligne 7 :</td>
<td colspan="2" class="diff-lineno">Ligne 7 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Epidémiologie:</u> 80% des leucémies chez l'enfant, 20% des leucémies chez l'adulte<ref name="SURF" /></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Epidémiologie:</u> 80% des leucémies chez l'enfant, 20% des leucémies chez l'adulte<ref name="SURF" /></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Frottis périphérique:</u></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Frottis périphérique:</u></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* <u>Complication:</u> syndrome de lyse tumorale</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* <u>Complication:</u> <ins class="diffchange diffchange-inline">[[</ins>syndrome de lyse tumorale<ins class="diffchange diffchange-inline">]]</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement:</u></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement:</u></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*# Induction d'une rémission complète</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*# Induction d'une rémission complète</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Leuc%C3%A9mies&diff=5124&oldid=prev
Julien : /* Leucémie myéloïde aiguë (LMA) */
2024-05-13T15:42:25Z
<p><span dir="auto"><span class="autocomment">Leucémie myéloïde aiguë (LMA)</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 13 mai 2024 à 15:42</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l42" >Ligne 42 :</td>
<td colspan="2" class="diff-lineno">Ligne 42 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Caractéristiques:</u> Association avec coagulopathie, [[coagulation intravasculaire disséminée (CIVD)]]. 7 types</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Caractéristiques:</u> Association avec coagulopathie, [[coagulation intravasculaire disséminée (CIVD)]]. 7 types</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** Bilan: cytométrie de flux, panel myéloïde</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** Bilan: cytométrie de flux, panel myéloïde</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* <u>Frottis périphérique:</u> Le diagnostic d’une LMA est posé si l’on trouve ≥20% de blastes myéloïdes dans la moelle ou le sang périphérique ou si une tumeur extramédullaire se compose de blastes myéloïdes.<ref>https://www.revmed.ch/RMS/2008/RMS-158/Les-leucemies-aigues</ref></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* <u>Frottis périphérique:</u> Le diagnostic d’une LMA est posé si l’on trouve <ins class="diffchange diffchange-inline">'''</ins>≥20% de blastes myéloïdes dans la moelle ou le sang périphérique<ins class="diffchange diffchange-inline">''' </ins>ou si une tumeur extramédullaire se compose de blastes myéloïdes.<ref>https://www.revmed.ch/RMS/2008/RMS-158/Les-leucemies-aigues</ref></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Complication:</u> syndrome de lyse tumorale</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Complication:</u> syndrome de lyse tumorale</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement:</u></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Traitement:</u></div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Leuc%C3%A9mies&diff=5123&oldid=prev
Julien : /* Lignée myéloïde */
2024-05-13T15:41:54Z
<p><span dir="auto"><span class="autocomment">Lignée myéloïde</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 13 mai 2024 à 15:41</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l40" >Ligne 40 :</td>
<td colspan="2" class="diff-lineno">Ligne 40 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Lignée myéloïde ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Lignée myéloïde ==</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Leucémie myéloïde aiguë (LMA) ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Leucémie myéloïde aiguë (LMA) ===</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* <u>Caractéristiques:</u> Association avec coagulopathie, CIVD. 7 types</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* <u>Caractéristiques:</u> Association avec coagulopathie, <ins class="diffchange diffchange-inline">[[coagulation intravasculaire disséminée (</ins>CIVD<ins class="diffchange diffchange-inline">)]]</ins>. 7 types</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** Bilan: cytométrie de flux, panel myéloïde</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** Bilan: cytométrie de flux, panel myéloïde</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Frottis périphérique:</u> Le diagnostic d’une LMA est posé si l’on trouve ≥20% de blastes myéloïdes dans la moelle ou le sang périphérique ou si une tumeur extramédullaire se compose de blastes myéloïdes.<ref>https://www.revmed.ch/RMS/2008/RMS-158/Les-leucemies-aigues</ref></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Frottis périphérique:</u> Le diagnostic d’une LMA est posé si l’on trouve ≥20% de blastes myéloïdes dans la moelle ou le sang périphérique ou si une tumeur extramédullaire se compose de blastes myéloïdes.<ref>https://www.revmed.ch/RMS/2008/RMS-158/Les-leucemies-aigues</ref></div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Leuc%C3%A9mies&diff=5122&oldid=prev
Julien : /* Leucémie lymphoblastique chronique (LLC) */
2024-05-13T15:40:03Z
<p><span dir="auto"><span class="autocomment">Leucémie lymphoblastique chronique (LLC)</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 13 mai 2024 à 15:40</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l30" >Ligne 30 :</td>
<td colspan="2" class="diff-lineno">Ligne 30 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>En rechute ou en première ligne:</u> Nouvelles molécules Ibrutinib = anti-BTK ou R-Idelalisib = anti-PI3K Premier choix pour les cas de del 17p ou mutation de p53</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>En rechute ou en première ligne:</u> Nouvelles molécules Ibrutinib = anti-BTK ou R-Idelalisib = anti-PI3K Premier choix pour les cas de del 17p ou mutation de p53</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Complications:</u></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* <u>Complications:</u></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>*; [[<del class="diffchange diffchange-inline">Microangiopathies_thrombotiques</del>#Purpura_thrombotique_thrombocytop.C3.A9nique_.28PTT.29|→ Purpura thrombotique thrombocytopénique]]</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>*; [[<ins class="diffchange diffchange-inline">Microangiopathies_thrombotiques_(MAT)</ins>#Purpura_thrombotique_thrombocytop.C3.A9nique_.28PTT.29|→ Purpura thrombotique thrombocytopénique]]</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*; → '''Transformation de Richter''': transformation en [[Lymphomes|lymphome]] à grandes cellules B de mauvais pronostic</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*; → '''Transformation de Richter''': transformation en [[Lymphomes|lymphome]] à grandes cellules B de mauvais pronostic</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*; → Hypogammaglobulinémie et infections: intravenous immunoglobulin G replacement therapy reduces the risk of infections in patients with chronic lymphocytic leukemia with documented hypogammaglobulinemia.</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*; → Hypogammaglobulinémie et infections: intravenous immunoglobulin G replacement therapy reduces the risk of infections in patients with chronic lymphocytic leukemia with documented hypogammaglobulinemia.</div></td></tr>
</table>
Julien